Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FGFR Mutation”

37 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 37 results

Testing effectiveness (Phase 2)Ended earlyNCT04003610
What this trial is testing

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Who this might be right for
Metastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
Incyte Corporation 7
Testing effectiveness (Phase 2)Study completedNCT02272998
What this trial is testing

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Who this might be right for
Malignant Neoplasm
Sameek Roychowdhury 22
Testing effectiveness (Phase 2)Ended earlyNCT02706691
What this trial is testing

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Who this might be right for
FGFR Gene AmplificationFGFR1 Gene AmplificationFGFR2 Gene Amplification+7 more
University of Chicago 1
Testing effectiveness (Phase 2)UnknownNCT04096417
What this trial is testing

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Who this might be right for
FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR1 Gene Translocation+16 more
Academic and Community Cancer Research United 14
Testing effectiveness (Phase 2)Ended earlyNCT01732107
What this trial is testing

Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

Who this might be right for
Bladder Cancer
Noah Hahn, M.D. 13
Testing effectiveness (Phase 2)Looking for participantsNCT07265947
What this trial is testing

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

Who this might be right for
Low Grade Upper Tract Urothelial Carcinoma
Tyra Biosciences, Inc 230
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06530823
What this trial is testing

Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma

Who this might be right for
Biliary Tract CarcinomaCholangiocarcinoma
Eastern Hepatobiliary Surgery Hospital 38
Large-scale testing (Phase 3)Ended earlyNCT03773302
What this trial is testing

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Who this might be right for
Advanced CholangiocarcinomaFGFR2 Gene Mutation
QED Therapeutics, a BridgeBio company 48
Testing effectiveness (Phase 2)Ended earlyNCT03822117
What this trial is testing

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Who this might be right for
Solid Tumor Malignancy
Incyte Corporation 111
Early research (Phase 1)Ended earlyNCT01948297
What this trial is testing

Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations

Who this might be right for
Solid Tumours
Debiopharm International SA 77
Testing effectiveness (Phase 2)Active Not RecruitingNCT05544552
What this trial is testing

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

Who this might be right for
Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaSolid Tumor+11 more
Tyra Biosciences, Inc 310
Early research (Phase 1)Looking for participantsNCT06915753
What this trial is testing

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Who this might be right for
Metastatic Hepatocellular CarcinomaSolid TumorsSolid Tumor, Adult+11 more
Tyra Biosciences, Inc 100
Testing effectiveness (Phase 2)UnknownNCT05004974
What this trial is testing

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

Who this might be right for
Advanced Non Small Cell Lung Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine 20
Testing effectiveness (Phase 2)Study completedNCT01831726
What this trial is testing

Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

Who this might be right for
Tumor Pathway Activations Inhibited by Dovitinib
Novartis Pharmaceuticals 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT06351371
What this trial is testing

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)

Who this might be right for
Malignant Solid Neoplasm
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Study completedNCT01752920
What this trial is testing

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Who this might be right for
Solid Tumor
Basilea Pharmaceutica 119
Large-scale testing (Phase 3)Study completedNCT02965378
What this trial is testing

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Who this might be right for
FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR2 Gene Amplification+5 more
SWOG Cancer Research Network 43
Not applicableUnknownNCT04339933
What this trial is testing

Detection of FGFR Gene Mutations in the Tumor Tissue and Urine of Patients With Urothelial Carcinoma

Who this might be right for
Bladder Cancer
Ho Kyung Seo 92
Testing effectiveness (Phase 2)Ended earlyNCT03827850
What this trial is testing

FGFR Inhibitor in FGFR Dysregulated Cancer

Who this might be right for
Lung CancerNSCLCPulmonary Neoplasm+2 more
Lung Cancer Group Cologne 22
Early research (Phase 1)Active Not RecruitingNCT06160752
What this trial is testing

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

Who this might be right for
Locally Advanced CholangiocarcinomaIntrahepatic CholangiocarcinomaSolid Tumor+1 more
Tyra Biosciences, Inc 40
Next Page